This is a preview of subscription content, log in via an institution to check access.
REFERENCE
St. Charles M, Minshall ME, Pandya BJ, Baran RW, Tunis SL.A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US. Current Medical Research and Opinion 25: 1343-1353, No. 6, Jun 2009
Rights and permissions
About this article
Cite this article
Metformin/pioglitazone a dominant diabetes strategy. Pharmacoecon. Outcomes News 584, 7 (2009). https://doi.org/10.2165/00151234-200905840-00020
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200905840-00020